Through 2020, the Asthma Drug Market Will Remain Flat Amidst Generic Erosion of Key Agents and Increased Product Competiti

Loss of Patent Exclusivity Will Reduce Sales of Branded Singulair by More Than $2 Billion in 2020, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the uptake of high-price once-daily combinations and novel anticytokine agents, generic erosion and increased product competition will lead to a relatively flat asthma drug market over the next decade. The overall asthma drug market will decrease slightly from $14.6 billion in 2010 to $14.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor advisory service entitled Asthma finds that the expiration of patent exclusivity for Merck/Kyorin’s Singulair—which garnered sales of $3.3 billion for asthma in 2010—will be a key constraint on the overall market as generic entry in the United States, Europe and Japan will reduce sales of branded Singulair by more than $2 billion in 2020.

“Despite the dramatic annual decline in sales of Singulair, emerging agents that offer the convenience of once-daily dosing will generate over $2.3 billion in sales in 2020 at the expense of market leaders that are dosed twice daily,” said Decision Resources Analyst Amanda Puffer, M.Sc. “Driving these sales will be the uptake of emerging once-daily LABA/ICS combinations, including GlaxoSmithKline/Theravance’s Relovair, and these gains will serve to offset the decline in sales due in part to the entry of generic Singulair.”

The findings also reveal that the launches and uptake of novel anticytokine agents will likely serve the severe, corticosteroid-refractory asthma population. Though the size of this population is limited, these novel agents will begin to fulfill an important unmet need for difficult-to-control patients and their launch signifies a move toward personalized medicine for the treatment of asthma.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Research  Science  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.